The global impact of Precision Medicine Group.
As it happens.
Impact, observations, and insights on the evolving healthcare landscape.
As more high-cost drugs, including one-time gene therapies, come onto the market, employers are considering implementing a variety of contracting models to make sure their employees have access to these agents. Precision’s Jorge Font and Erin Lopata explore these innovative new approaches, as well as the challenges in executing them.
Every month, MassBio spotlights a member company and the great work they’re doing to advance the life sciences industry and support the patients they serve. In May, MassBio put the spotlight on Precision Value & Health with a Q&A with Precision’s Kelly Wilder.
Increasingly, stakeholders across the healthcare continuum are recognizing the importance of social determinants of health (SDOH) on outcomes and quality of life.
In this white paper from Precision’s Maureen Hennessey, we use the results of a 2019 PRECISIONvalue survey and a subsequent 2020 post-onset of COVID-19 survey to evaluate perspectives on SDOH and assess the progress of programs to address SDOH.
The growing skills gaps in cell and gene therapy have resulted in a bottleneck preventing potentially revolutionary treatments from reaching the patients who need them. Phil Massey and Daniel Foody of Project Farma, part of the Precision ADVANCE collective, weigh in on the effects of the talent gap, and discuss strategies for closing the gap.
Due to their complexity and cost, developers of cell and gene therapies face unique manufacturing hurdles. Determining the right approach to manufacturing is crucial when bringing these advanced therapeutics from clinical to commercialization.
This white paper, based on a recent webinar co-sponsored by Precision for Medicine and Informa Pharma Intelligence, features the unique expertise of Erin Harris (Editor In Chief of Cell & Gene), David Carr (Director, PRECISIONadvisors), Tony Khoury (Executive Vice President, Project Farma), Janet Lambert (CEO, Alliance for Regenerative Medicine), and Alex Karnal (Partner and Managing Director, Deerfield Management).
Calculating viral vector yields is essential to determine how much drug product is needed for a specific gene therapy. It’s a critical analysis for any gene therapy organization looking to scale from preclinical to clinical to commercial. Project Farma’s Tony Khoury, Christian Hermanas and Salome Philip provide an in depth review of a valuable yield calculation tool that can serve as a vital prerequisite of the “make vs buy” analysis.
Although clinical trials in the cell and gene therapy space have skyrocketed, there’s a significant shortfall in the skilled talent required to execute on the exponential potential of cell and gene therapies. Project Farma and Precision ADVANCE leaders Anshul Mangal and John Khoury discuss the biotherapeutic process and manufacturing talent gap, and propose a multipronged approach to addressing the problem through internal innovation and the external influence of academia and industry associations.
The cell and gene therapy manufacturing skills shortage is slowing the abilities of innovative therapies to reach patients, delaying manufacturing scaleup and increasing learning and development costs. Project Farma’s Anshul Mangal discusses the impact of the cell and gene therapy manufacturing skills shortage, and reviews ways to scale up and bring more therapies to commercialization despite the skills gap.
A big bottleneck in the evolving field of cell and gene therapy is identifying sites with the capability and capacity to conduct these resource-intensive studies. Gene and cell therapy developers need to create clinical interest to find champions at investigative sites and differentiate their products and clinical trials to keep development moving forward. Precision’s Megan Liles explores strategies for building clinical enthusiasm and selecting the right sites for gene and cell therapy trials.